BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37895147)

  • 21. Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults.
    Cao XX; Sun J; Li J; Zhong DR; Niu N; Duan MH; Liang ZY; Zhou DB
    Ann Hematol; 2016 Apr; 95(5):745-50. PubMed ID: 26858028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation.
    Hervier B; Haroche J; Arnaud L; Charlotte F; Donadieu J; Néel A; Lifermann F; Villabona C; Graffin B; Hermine O; Rigolet A; Roubille C; Hachulla E; Carmoi T; Bézier M; Meignin V; Conrad M; Marie L; Kostrzewa E; Michot JM; Barete S; Taly V; Cury K; Emile JF; Amoura Z;
    Blood; 2014 Aug; 124(7):1119-26. PubMed ID: 24894769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era.
    Goyal G; Heaney ML; Collin M; Cohen-Aubart F; Vaglio A; Durham BH; Hershkovitz-Rokah O; Girschikofsky M; Jacobsen ED; Toyama K; Goodman AM; Hendrie P; Cao XX; Estrada-Veras JI; Shpilberg O; Abdo A; Kurokawa M; Dagna L; McClain KL; Mazor RD; Picarsic J; Janku F; Go RS; Haroche J; Diamond EL
    Blood; 2020 May; 135(22):1929-1945. PubMed ID: 32187362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An effective treatment in Erdheim Chester disease: vemurafenib: a case report.
    Bozan E; Darçın T; Yaman S; Yiğenoğlu TN; Kızıl Çakar M; Dal MS; Altuntaş F
    J Med Case Rep; 2023 Oct; 17(1):426. PubMed ID: 37821987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erdheim-Chester disease.
    Brychtová M; Vlachová M; Gregorová J; Krejčí M; Adam Z; Ševčíková S
    Klin Onkol; 2021; 34(6):434-439. PubMed ID: 34911328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erdheim-Chester disease.
    Haroche J; Arnaud L; Cohen-Aubart F; Hervier B; Charlotte F; Emile JF; Amoura Z
    Curr Rheumatol Rep; 2014 Apr; 16(4):412. PubMed ID: 24532298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erdheim-Chester disease with bilateral orbital masses and multi-systemic symptoms: two case reports.
    Qiao J; Ma R; Peng X; He W
    World J Surg Oncol; 2023 Jul; 21(1):233. PubMed ID: 37525276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An NRAS mutation in a case of Erdheim-Chester disease.
    Aitken SJ; Presneau N; Tirabosco R; Amary MF; O'Donnell P; Flanagan AM
    Histopathology; 2015 Jan; 66(2):316-9. PubMed ID: 24754681
    [No Abstract]   [Full Text] [Related]  

  • 29. Impact of
    Razanamahery J; Godot A; Leguy-Seguin V; Samson M; Audia S; Bonnotte B
    Front Immunol; 2023; 14():1260193. PubMed ID: 37809108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease.
    Cohen Aubart F; Emile JF; Maksud P; Galanaud D; Cluzel P; Benameur N; Aumaitre O; Amoura Z; Haroche J
    Br J Haematol; 2018 Jan; 180(1):150-153. PubMed ID: 27711968
    [No Abstract]   [Full Text] [Related]  

  • 31. FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the
    Oneal PA; Kwitkowski V; Luo L; Shen YL; Subramaniam S; Shord S; Goldberg KB; McKee AE; Kaminskas E; Farrell A; Pazdur R
    Oncologist; 2018 Dec; 23(12):1520-1524. PubMed ID: 30120160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erdheim-Chester Disease: A Case Report of BRAF V600E-Negative, MAP2K1-Positive ECD Diagnosed by Blood Next-Generation Sequencing Assay and a Brief Literature Review.
    Aggarwal A; Taychert M; Hasanin L; Doll D; Basuino MG; Hasanein H
    Oncology (Williston Park); 2023 Jul; 37(7):298-302. PubMed ID: 37499251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cladribine treatment for Erdheim-Chester disease involving the central nervous system and concomitant polycythemia vera: A case report.
    Tamura S; Kawamoto K; Miyoshi H; Suzuki T; Katagiri T; Kasami T; Nemoto H; Miyakoshi S; Kobayashi H; Shibasaki Y; Masuko M; Takeuchi K; Ohshima K; Sone H; Takizawa J
    J Clin Exp Hematop; 2018 Dec; 58(4):161-165. PubMed ID: 30305475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series.
    Bhatia A; Hatzoglou V; Ulaner G; Rampal R; Hyman DM; Abdel-Wahab O; Durham BH; Dogan A; Ozkaya N; Yabe M; Petrova-Drus K; Panageas KS; Reiner A; Rosenblum M; Diamond EL
    Neuro Oncol; 2020 Jul; 22(7):979-992. PubMed ID: 31950179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Use of targeting therapy in Erdheim-Chester disease: A case report with neurologic involvement].
    Berthe P; Rouzic N; Daelman L; Jacobzone C; Espitia A; Cohen-Aubart F; Haroche J; Émile JF; Lorleac'h A
    Rev Med Interne; 2020 Jun; 41(6):413-417. PubMed ID: 32113636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both
    Nordmann TM; Juengling FD; Recher M; Berger CT; Kalbermatten D; Wicki A; Paasinen-Sohns A; Cathomas G; Tzankov A; Daikeler T
    Blood; 2017 Feb; 129(7):879-882. PubMed ID: 27940476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
    Diamond EL; Subbiah V; Lockhart AC; Blay JY; Puzanov I; Chau I; Raje NS; Wolf J; Erinjeri JP; Torrisi J; Lacouture M; Elez E; Martínez-Valle F; Durham B; Arcila ME; Ulaner G; Abdel-Wahab O; Pitcher B; Makrutzki M; Riehl T; Baselga J; Hyman DM
    JAMA Oncol; 2018 Mar; 4(3):384-388. PubMed ID: 29188284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease.
    Picarsic J; Pysher T; Zhou H; Fluchel M; Pettit T; Whitehead M; Surrey LF; Harding B; Goldstein G; Fellig Y; Weintraub M; Mobley BC; Sharples PM; Sulis ML; Diamond EL; Jaffe R; Shekdar K; Santi M
    Acta Neuropathol Commun; 2019 Nov; 7(1):168. PubMed ID: 31685033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis.
    Aaroe A; Kurzrock R; Goyal G; Goodman AM; Patel H; Ruan G; Ulaner G; Young J; Li Z; Dustin D; Go RS; Diamond EL; Janku F
    Blood Adv; 2023 Aug; 7(15):3984-3992. PubMed ID: 36857436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erdheim-Chester disease: a comprehensive review from the ophthalmologic perspective.
    Kanakis M; Petrou P; Lourida G; Georgalas I
    Surv Ophthalmol; 2022; 67(2):388-410. PubMed ID: 34081930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.